Veru (NASDAQ:VERU) Stock Picked Up by Analysts at Westpark Capital

Equities researchers at Westpark Capital began coverage on shares of Veru (NASDAQ:VERU) in a research report issued on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating on the stock.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings raised shares of Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.50.

Veru Price Performance

VERU traded down $0.08 during midday trading on Tuesday, reaching $2.47. 1,517,504 shares of the company’s stock traded hands, compared to its average volume of 736,582. Veru has a 52 week low of $2.05 and a 52 week high of $7.33. The firm has a fifty day moving average of $2.54 and a two-hundred day moving average of $2.53. The stock has a market capitalization of $42.11 million, a price-to-earnings ratio of -3.58 and a beta of -1.21.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Sell-side analysts forecast that Veru will post -1.07 EPS for the current year.

Institutional Trading of Veru

A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its stake in shares of Veru by 69.3% in the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after acquiring an additional 5,008 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Veru in the first quarter worth about $153,000. Finally, FNY Investment Advisers LLC purchased a new stake in Veru in the second quarter worth about $328,000. Institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.